Gilead Sciences and Verily Life Sciences have begun a scientific collaboration using Verily’s Immunoscape, a platform for generating immunological data and insights, to identify and better understand the immunological basis of inflammatory diseases rheumatoid arthritis, inflammatory bowel disease and lupus. Gilead will pay up to $90 million over three years to Verily, who will analyze biological samples and clinical disease and treatment response data from patients participating in Gilead's clinical trials. This three-year collaboration represents the broadest effort to date to interrogate the activity of specific subtypes of immune cells to better understand disease signatures and treatment response.
Immunoscape combines immunogenomic phenotyping and advanced computational analysis techniques to profile the molecular characteristics of inflammatory diseases at high resolution. Through the collaboration, Gilead will provide clinical data and thousands of immune cell samples from participants before, during and after administration of novel drugs in the company’s ongoing Phase 2 and Phase 3 clinical studies.
All data and samples will be coded to protect patient privacy, and any findings of the analysis will include patient data only in aggregate.
Read the press release